gantenerumab discontinued
Selected indexed studies
- Donanemab: Appropriate use recommendations. (J Prev Alzheimers Dis, 2025) [PMID:40155270]
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. (Lancet Neurol, 2025) [PMID:40120616]
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics. (J Prev Alzheimers Dis, 2025) [PMID:40011173]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Donanemab: Appropriate use recommendations. (2025) pubmed
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. (2025) pubmed
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics. (2025) pubmed
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. (2025) pubmed
- A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. (2017) pubmed
- Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy. (2022) pubmed
- Passive antiamyloid immunotherapy for Alzheimer's disease. (2020) pubmed
- Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. (2022) pubmed
- Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? (2014) pubmed